中文版
|
English
Home
Products
About us
Support
Custom Synthesis
Contact
A
B
C
D
E
F
G
H
I
L
O
P
R
S
T
V
W
X
Y
Pharmacology
Transporters
Nuclear Receptors
Ion Channels
7-TM Receptors
Aurora Kinase Inhibitors
Activators
Cell Cycle/Checkpoint
CETP inhibitor
PI3K/Akt/mTOR
Angiogenesis/Tyrosine Kinase
HDAC
Cytochrome P450
Apoptosis
Proteases/HSP90/HSP70
Wnt/Hedgehog/Notch
Other Pharmacology
Research Area
Immunology
Infection
Cardiovascular Disease
Antivirals
Cancer
Product Type
Peptides
Natural Compounds
Product Information
Home
>>>
Product Class
>>>
Pharmacology
>>> 
Other Pharmacology
>>> 
sPLA2
C13850 Varespladib(LY315920,LY-333013)
Synonyms:LY-315920, LY-333013
CAS No.:172732-68-2
Molecular Formula:C21H20N2O5
Molecular Weight:380.40
Solubility:Soluble in DMSO
Appearance:White powder
Purity:>99%
Pakage:5mg,10mg,20mg
Storage:at -20℃ 2 years
Varespladib(LY315920,LY-333013) Introduction:
Chemical Name: [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid
Varespladib is a selective inhibitor of human, group IIA, nonpancreatic secretory PLA2 (sPLA2). In a chromogenic isolated enzyme assay, Varespladib inhibited sPLA2 activity with an IC50 of 9 6 ±1 nM or 7.3 *10-6 mole fraction, which approached the stiochiometric limit of this assay.Varespladib was 40-fold less active against human, group IB, pancreatic sPLA2 and was inactive against cytosolic PLA2 and the constitutive and inducible forms of cyclooxygenase.Human sPLA2-induced release of thromboxane A2 (TXA2) from isolated guinea pig lung bronchoalveolar lavage cells was inhibited by Varespladib with an IC50 of 0.79 nM. Therefore£¬the use of Varespladib have a beneficial effect in preventing various inflammatory disease states.
Related Article:
Related Products:
C13850 Varespladib(LY315920,LY-333013)
Copyright© 2003-2019
Chembest Research Laboratories Limited
All rights reserved. 沪ICP备11035973号
Tel :+86-21-20908456
Fax:+86-21-58180499-808
Address:No.3377 Kangxin Road, Pudong New District,Shanghai,China
PostCode:201318